Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 2,500 Shares

Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. This represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vericel Stock Down 0.8 %

NASDAQ VCEL opened at $58.62 on Tuesday. The business’s fifty day simple moving average is $46.41 and its 200-day simple moving average is $47.07. The firm has a market cap of $2.89 billion, a PE ratio of 977.00 and a beta of 1.66. Vericel Co. has a 52 week low of $32.31 and a 52 week high of $61.49.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. The business had revenue of $57.91 million during the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. Research analysts expect that Vericel Co. will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Vericel

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. International Assets Investment Management LLC raised its holdings in Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares during the period. CWM LLC increased its position in shares of Vericel by 319.0% during the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 504 shares during the last quarter. Farther Finance Advisors LLC raised its stake in shares of Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Vericel by 22.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 322 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in shares of Vericel during the 3rd quarter worth approximately $92,000.

Analysts Set New Price Targets

A number of research firms have weighed in on VCEL. Canaccord Genuity Group began coverage on shares of Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 price objective for the company. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Canaccord Genuity Group reissued a “buy” rating and issued a $60.00 price objective on shares of Vericel in a report on Tuesday, November 19th. TD Cowen upped their target price on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Vericel in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $58.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.